When was RenovoDerm founded?

RenovoDerm was founded in 2016 and raised its 1st funding round 1 year after it was founded.

Where is RenovoDerm located?

RenovoDerm is headquartered in Columbus, United States.

How many employees does RenovoDerm have?

As of Mar 31, 2026, the latest employee count at RenovoDerm is 5.

Is RenovoDerm a funded company?

RenovoDerm is a funded company, having raised a total of $775K across 4 funding rounds to date. The company's 1st funding round was a $***** Seed round, raised on Jun 2017.

When was the latest funding round of RenovoDerm?

RenovoDerm's latest funding was a $***** Conventional Debt round on May 09, 2024, with participation from 0 investor.

Where does RenovoDerm rank among its competitors?

RenovoDerm ranks 25th amongst 85 active competitors, of which 30 are funded. It stands 9th in terms of total funding among its competitors. The most recent competitor to raise funding was GeniPhys, which secured $3M in Jan, 2026.

Who are the top competitors of RenovoDerm?

RenovoDerm's top competitors include Imbed Biosciences, NanoSyrinx and Organogenesis. Among them, GeniPhys secured the most recent funding round in January, 2026.

RenovoDerm - 2026 Company Profile, Team, Funding & Competitors

RenovoDerm is a seed company based in Columbus (United States), founded in 2016 by Jed Johnson. It operates as a Developer of nanofiber-based wound care devices. RenovoDerm has raised $775K in funding. The company has 85 active competitors, including 30 funded and 6 that have exited. Its top competitors include companies like Imbed Biosciences, NanoSyrinx and Organogenesis.

Company Details

Developer of nanofiber-based wound care devices. It develops Phoenix Wound Matrix, a nanofiber product that mimics the extracellular matrix found naturally in the body. It can be used for the treatment of pressure ulcers, venous ulcers, diabetic ulcers, chronic vascular ulcers, tunneled or undermined wounds, surgical wounds, and trauma wounds.

Website: www.renovoderm.tech/
Phone Number: +1 **********

Key Metrics

Founded Year

2016

Location

Columbus, United States

Stage

Seed

Total Funding

$775K in 4 rounds

Latest Funding Round

Conventional Debt, May 09, 2024, $*****

Investors

Monte Carlo Capital & 2 more

Ranked

25^th among 85 active competitors

Employee Count

5 as on Mar 31, 2026

Similar Companies

Imbed Biosciences & 100 more

View RenovoDerm's full profile

RenovoDerm is associated with 1 legal entity given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
RenovoDerm, LLC CIN: 814676887 , United States, Active	Dec 31, 2015	-	-	-

RenovoDerm has raised a total funding of $775K over 4 rounds. Its first funding round was on Jun 2017. RenovoDerm has 3 institutional investors.

Here is the list of recent funding rounds of RenovoDerm:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
May 09, 2024	2652118	Conventional Debt	2853747	5952671	3117321	7591486
Jan 25, 2023	5450714	Seed	2130068	6606533	9788895	3474611
Jan 25, 2021	8858060	Seed	5063567	9086087	6827655	3792340

Access funding benchmarks and valuations. Sign up today!

View details of RenovoDerm's funding rounds and investors

The founders of RenovoDerm is Jed Johnson.

Here are the details of RenovoDerm's key team members:

Jed Johnson: Co-Founder and CTO of RenovoDerm and founder of 1 other company.
Ross Kayuha: CEO of RenovoDerm.
Contact Info: 1 email address

View details of RenovoDerm's Founder profiles and Board Members

RenovoDerm's employee count trend

RenovoDerm has 5 employees as of Mar 26. Here is RenovoDerm's employee count trend over the years:

Uncover RenovoDerm's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of RenovoDerm include Imbed Biosciences, NanoSyrinx and Organogenesis. Here is the list of Top 10 competitors of RenovoDerm, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Imbed Biosciences 2010, Madison (United States), Series C	Provider of nanotech-based wound care products	$34.3M	Niterra, MassChallenge & 7 others	70/100
2nd	NanoSyrinx 2018, Coventry (United Kingdom), Series A	Developer of targeted intracellular delivery platform for biological molecules	$21.6M	Octopus Ventures, M Ventures & 15 others	61/100
3rd	Organogenesis 1985, Canton (United States), Public	Regenerative tissue innovations for advanced wound care and surgical solutions	$30M	Spring St. Group, Eastward Capital Partners ... & 2 others	60/100
4th	Acera Surgical 2013, St. Louis (United States), Acquired	Provider of synthetic electrospun scaffolds for regenerative medical applications	$6.32M	St. Louis Arch Angels, Missouri Technology ... & 1 others	57/100
5th	BioTissue 2001, Miami (United States), Series C	Developer of regenerative biologic therapies for eye care	$110M	Ballast Point Ventures, RC Capital & 2 others	52/100
6th	GeniPhys 2014, Zionsville (United States), Series A	Developer of collagen polymers for tissue regeneration	$13.5M	Elevate Ventures, America’s Seed Fund & 3 others	52/100
7th	Cellics 2014, San Diego (United States), Series B	Developing therapies for infectious diseases & autoimmune disorders using Nanosponge technology	$26M	CARB-X, Cash Capital	49/100
8th	Humanetics Corporation 1988, Minneapolis (United States), Funding Raised	Clinical-stage biopharma company developing radiation modulators as therapeutics for solid cancers	-	National Heart Lung and Blood Institute, Defense.gov ... & 4 others	46/100
9th	Marizyme 2007, Woodstock (United States), Public	Developer of therapy for the treatment of chronic wounds, thrombolysis, and dental health	-	-	46/100
10th	Cour Pharma 2013, Chicago (United States), Series A	Developer of biotech nano-particles for immune diseases	$135M	Pfizer, Bristol-Myers Squibb & 6 others	45/100
25th	RenovoDerm 2016, Columbus (United States), Seed	Developer of nanofiber-based wound care devices	$775K	Monte Carlo Capital, Proton Enterprises & 1 others	34/100